MX368199B - Formulación en polvo seco que comprende un corticoesteroide y un beta-adrenérgico para administración por inhalación. - Google Patents

Formulación en polvo seco que comprende un corticoesteroide y un beta-adrenérgico para administración por inhalación.

Info

Publication number
MX368199B
MX368199B MX2016001311A MX2016001311A MX368199B MX 368199 B MX368199 B MX 368199B MX 2016001311 A MX2016001311 A MX 2016001311A MX 2016001311 A MX2016001311 A MX 2016001311A MX 368199 B MX368199 B MX 368199B
Authority
MX
Mexico
Prior art keywords
corticosteroid
dry powder
adrenergic
inhalation
beta
Prior art date
Application number
MX2016001311A
Other languages
English (en)
Inventor
Monari Elisa
Maria Cantarelli Anna
Cocconi Daniela
Pasquali Irene
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47715987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX368199(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX368199B publication Critical patent/MX368199B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una formulación en polvo seco que comprende corticoesteroide y un fármaco adrenérgico beta2 en combinación, su proceso de preparación, y usos terapéuticos de la misma.
MX2016001311A 2012-01-25 2013-01-23 Formulación en polvo seco que comprende un corticoesteroide y un beta-adrenérgico para administración por inhalación. MX368199B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12152392 2012-01-25
PCT/EP2013/051187 WO2013110632A1 (en) 2012-01-25 2013-01-23 Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation

Publications (1)

Publication Number Publication Date
MX368199B true MX368199B (es) 2019-09-24

Family

ID=47715987

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016001311A MX368199B (es) 2012-01-25 2013-01-23 Formulación en polvo seco que comprende un corticoesteroide y un beta-adrenérgico para administración por inhalación.
MX2014008631A MX355729B (es) 2012-01-25 2013-01-23 Formulacion en polvo seco que comprende un corticoesteroide y un beta-adrenergico para administracion por inhalacion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014008631A MX355729B (es) 2012-01-25 2013-01-23 Formulacion en polvo seco que comprende un corticoesteroide y un beta-adrenergico para administracion por inhalacion.

Country Status (38)

Country Link
US (3) US10028964B2 (es)
EP (7) EP3020394A1 (es)
JP (1) JP6104282B2 (es)
KR (3) KR101560288B1 (es)
CN (2) CN105726548B (es)
AR (1) AR089805A1 (es)
AU (1) AU2013211656B2 (es)
BR (1) BR112014017481A8 (es)
CA (1) CA2862548C (es)
CL (1) CL2014001966A1 (es)
CO (1) CO7010836A2 (es)
CY (1) CY1120684T1 (es)
DK (5) DK3412277T3 (es)
EA (2) EA026267B1 (es)
ES (5) ES2929137T3 (es)
FI (1) FI3412277T3 (es)
GE (1) GEP201706767B (es)
HK (1) HK1200021A1 (es)
HR (5) HRP20230147T1 (es)
HU (5) HUE040525T2 (es)
IL (1) IL233784A0 (es)
LT (5) LT3412277T (es)
MA (1) MA35859B1 (es)
MX (2) MX368199B (es)
MY (1) MY165888A (es)
NZ (1) NZ627837A (es)
PE (1) PE20141703A1 (es)
PH (1) PH12014501565A1 (es)
PL (5) PL3527197T3 (es)
PT (5) PT3527196T (es)
RS (5) RS63759B1 (es)
SG (1) SG11201404350PA (es)
SI (2) SI2806855T1 (es)
TN (1) TN2014000322A1 (es)
TW (1) TWI559940B (es)
UA (1) UA115543C2 (es)
WO (1) WO2013110632A1 (es)
ZA (1) ZA201405464B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105726548B (zh) * 2012-01-25 2019-05-14 奇斯药制品公司 用于吸入给药包含皮质类固醇和beta-肾上腺素能药物的干粉配制剂
SI3019153T1 (sl) 2013-07-11 2018-12-31 Chiesi Farmaceutici S.P.A. Formulacija suhega praška, obsegajoča antiholinergik, kortikosteroid in beta-adrenergik, za dajanje z inhalacijo
UA118861C2 (uk) * 2013-12-06 2019-03-25 Оріон Корпорейшн Спосіб отримання сухих порошкових композицій для інгаляцій
EA035740B1 (ru) 2014-10-08 2020-08-03 Ератеч С.Р.Л. Состав для повышения стабильности лекарственного препарата, содержащий по меньшей мере один сухой порошок, полученный распылительной сушкой
CN109789107B (zh) * 2016-09-29 2021-12-03 广东东阳光药业有限公司 药物组合物
KR102637303B1 (ko) * 2017-05-11 2024-02-20 키에시 파르마슈티시 엣스. 피. 에이. 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
WO2019067866A1 (en) * 2017-09-29 2019-04-04 Crititech, Inc. GLUCOCORTICOID PARTICLES AND THEIR USE
EP3833964B1 (en) * 2018-08-07 2023-07-26 Norton (Waterford) Limited Application of raman spectroscopy for the manufacture of inhalation powders
EP3873574B1 (en) 2018-10-30 2023-12-06 Chiesi Farmaceutici S.p.A. Apparatus to administer drugs to mechanically ventilated patients
WO2021058454A1 (en) 2019-09-24 2021-04-01 Chiesi Farmaceutici S.P.A. Novel carrier particles for dry powder formulations for inhalation
AU2021324395A1 (en) 2020-08-14 2023-03-16 Norton (Waterford) Limited An inhalable formulation of fluticasone propionate and albuterol sulfate
WO2023117967A1 (en) * 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
CA2347856C (en) * 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
ATE326251T1 (de) 2002-07-31 2006-06-15 Chiesi Farma Spa Pulverinhalator
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
EP1982709A1 (en) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
WO2010097188A1 (en) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
GB0914240D0 (en) * 2009-08-14 2009-09-30 Breath Ltd Steroid solvates
RS54721B1 (en) * 2009-10-02 2016-08-31 Chiesi Farmaceutici S.P.A. PHARMACEUTICAL AEROSOL FORMOTEROL FORMULATION AND BECLOMETHASONE DIPROPIONATE
KR101730684B1 (ko) * 2010-04-01 2017-04-26 키에시 파르마슈티시 엣스. 피. 에이. 흡입용 건조 분말을 위한 담체 입자 제조 방법
RU2580312C2 (ru) 2010-04-21 2016-04-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ получения частиц с пониженным электростатическим зарядом
CN105726548B (zh) * 2012-01-25 2019-05-14 奇斯药制品公司 用于吸入给药包含皮质类固醇和beta-肾上腺素能药物的干粉配制剂
SI3019153T1 (sl) * 2013-07-11 2018-12-31 Chiesi Farmaceutici S.P.A. Formulacija suhega praška, obsegajoča antiholinergik, kortikosteroid in beta-adrenergik, za dajanje z inhalacijo

Also Published As

Publication number Publication date
ZA201405464B (en) 2015-12-23
HRP20230147T1 (hr) 2023-03-31
PH12014501565B1 (en) 2014-10-08
EP3527196B1 (en) 2022-09-07
PT3527197T (pt) 2022-10-26
EP3412277B1 (en) 2022-12-14
LT3527196T (lt) 2022-11-25
EP3527199B1 (en) 2022-09-07
LT3527197T (lt) 2022-11-25
SI3412277T1 (sl) 2023-03-31
PT3527199T (pt) 2022-11-08
LT2806855T (lt) 2018-10-10
CA2862548A1 (en) 2013-08-01
NZ627837A (en) 2016-04-29
HUE060402T2 (hu) 2023-02-28
US10028964B2 (en) 2018-07-24
RS57637B1 (sr) 2018-11-30
HUE040525T2 (hu) 2019-03-28
MA35859B1 (fr) 2014-12-01
WO2013110632A1 (en) 2013-08-01
HRP20221432T1 (hr) 2023-01-06
RS63952B1 (sr) 2023-02-28
EA201491281A1 (ru) 2014-12-30
HUE061566T2 (hu) 2023-07-28
PH12014501565A1 (en) 2014-10-08
AU2013211656A1 (en) 2014-07-24
EA026267B1 (ru) 2017-03-31
PL3527196T3 (pl) 2022-11-21
CL2014001966A1 (es) 2014-11-14
PL3412277T3 (pl) 2023-06-19
RS63706B1 (sr) 2022-11-30
DK2806855T3 (en) 2018-09-03
AR089805A1 (es) 2014-09-17
US20180296573A1 (en) 2018-10-18
DK3412277T3 (da) 2023-02-20
LT3527199T (lt) 2022-12-12
TW201334810A (zh) 2013-09-01
KR20140114374A (ko) 2014-09-26
ES2683254T3 (es) 2018-09-25
PT3527196T (pt) 2022-10-18
LT3412277T (lt) 2023-04-25
RS63761B1 (sr) 2022-12-30
PL3527199T3 (pl) 2022-12-12
FI3412277T3 (fi) 2023-03-23
US20150164915A1 (en) 2015-06-18
DK3527197T3 (da) 2022-10-24
GEP201706767B (en) 2017-11-10
KR101895279B1 (ko) 2018-09-05
DK3527199T3 (da) 2022-10-24
PE20141703A1 (es) 2014-11-24
EP3527197A1 (en) 2019-08-21
CN104080444A (zh) 2014-10-01
AU2013211656B2 (en) 2017-07-13
EP3527197B1 (en) 2022-09-07
EA201690187A1 (ru) 2016-05-31
KR101560288B1 (ko) 2015-10-14
EP2806855B1 (en) 2018-07-11
KR101786586B1 (ko) 2017-10-18
EP3527196A1 (en) 2019-08-21
UA115543C2 (uk) 2017-11-27
CN104080444B (zh) 2017-06-20
TN2014000322A1 (en) 2015-12-21
BR112014017481A2 (pt) 2017-06-13
SI2806855T1 (sl) 2018-11-30
CN105726548A (zh) 2016-07-06
RS63759B1 (sr) 2022-12-30
HUE060705T2 (hu) 2023-04-28
MX355729B (es) 2018-04-27
TWI559940B (en) 2016-12-01
EP2806855A1 (en) 2014-12-03
CA2862548C (en) 2020-07-07
EP3412277A1 (en) 2018-12-12
HRP20221433T1 (hr) 2023-01-06
US20130189324A1 (en) 2013-07-25
ES2929137T3 (es) 2022-11-25
ES2928688T3 (es) 2022-11-22
HRP20181550T1 (hr) 2018-11-30
PT3412277T (pt) 2023-02-14
CO7010836A2 (es) 2014-07-31
ES2938466T3 (es) 2023-04-11
EP3527199A1 (en) 2019-08-21
EP3020394A1 (en) 2016-05-18
IL233784A0 (en) 2014-09-30
HK1200021A1 (en) 2015-07-31
MY165888A (en) 2018-05-18
CN105726548B (zh) 2019-05-14
CY1120684T1 (el) 2019-12-11
SG11201404350PA (en) 2014-08-28
ES2929807T3 (es) 2022-12-01
DK3527196T3 (da) 2022-10-24
BR112014017481A8 (pt) 2021-06-15
PL2806855T3 (pl) 2018-12-31
HUE060421T2 (hu) 2023-02-28
HRP20221431T1 (hr) 2023-01-06
JP2015508416A (ja) 2015-03-19
KR20170116234A (ko) 2017-10-18
EA031566B1 (ru) 2019-01-31
EP3527198A1 (en) 2019-08-21
KR20150089093A (ko) 2015-08-04
JP6104282B2 (ja) 2017-03-29
MX2014008631A (es) 2014-08-21
PT2806855T (pt) 2018-09-28
US8778402B2 (en) 2014-07-15
PL3527197T3 (pl) 2022-11-21
US10946029B2 (en) 2021-03-16

Similar Documents

Publication Publication Date Title
TN2014000322A1 (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
PH12016500043A1 (en) Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-andrenergic for administration by inhalation
WO2014007770A3 (en) Inhalation compositions comprising corticosteroid and sorbitol
WO2014007772A3 (en) Inhalation compositions comprising glucose anhydrous
WO2014007781A3 (en) Inhalation compositions
WO2014007771A3 (en) Inhalation compositions comprising muscarinic receptor antagonist
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
PT2617451T (pt) Conjunto para administrar um medicamento e inalador de dose única para a administração de um medicamento em pó que tenha esse conjunto